High-Grade Glioma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘High-Grade Glioma – Pipeline Review, H1 2017’, provides an overview of the High-Grade Glioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma

The report reviews pipeline therapeutics for High-Grade Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved High-Grade Glioma therapeutics and enlists all their major and minor projects

The report assesses High-Grade Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for High-Grade Glioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

Athenex Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

BTG Plc

Cavion LLC

CBT Pharmaceuticals Inc

Concordia International Corp

DelMar Pharmaceuticals Inc

Ipsen SA

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

High-Grade Glioma - Overview

High-Grade Glioma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

High-Grade Glioma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High-Grade Glioma - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

Athenex Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

BTG Plc

Cavion LLC

CBT Pharmaceuticals Inc

Concordia International Corp

DelMar Pharmaceuticals Inc

Ipsen SA

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

High-Grade Glioma - Drug Profiles

AdRTSIL-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bendamustine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabazitaxel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Gliomas - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for High-Grade Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenolanib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYT-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dianhydrogalactitol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-7888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etirinotecan pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine + TBio-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GB-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSV-1716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride + TBio-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mibefradil dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

R&D Progress

Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel trevatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

porfimer sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

High-Grade Glioma - Dormant Projects

High-Grade Glioma - Discontinued Products

High-Grade Glioma - Product Development Milestones

Featured News & Press Releases

May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting

Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia

Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma

Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings

Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings

Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy

Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings

May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings

May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting

Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences

Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology

Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology

Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma

Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

May 28, 2015: Cavion to Present Clinical Trial Data at ASCO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for High-Grade Glioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

High-Grade Glioma – Pipeline by Advenchen Laboratories LLC, H1 2017

High-Grade Glioma – Pipeline by AngioChem Inc, H1 2017

High-Grade Glioma – Pipeline by Arog Pharmaceuticals Inc, H1 2017

High-Grade Glioma – Pipeline by Astellas Pharma Inc, H1 2017

High-Grade Glioma – Pipeline by Athenex Inc, H1 2017

High-Grade Glioma – Pipeline by Bayer AG, H1 2017

High-Grade Glioma – Pipeline by Boehringer Ingelheim GmbH, H1 2017

High-Grade Glioma – Pipeline by Bristol-Myers Squibb Company, H1 2017

High-Grade Glioma – Pipeline by BTG Plc, H1 2017

High-Grade Glioma – Pipeline by Cavion LLC, H1 2017

High-Grade Glioma – Pipeline by CBT Pharmaceuticals Inc, H1 2017

High-Grade Glioma – Pipeline by Concordia International Corp, H1 2017

High-Grade Glioma – Pipeline by DelMar Pharmaceuticals Inc, H1 2017

High-Grade Glioma – Pipeline by Ipsen SA, H1 2017

High-Grade Glioma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

High-Grade Glioma – Pipeline by Nektar Therapeutics, H1 2017

High-Grade Glioma – Pipeline by Novartis AG, H1 2017

High-Grade Glioma – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

High-Grade Glioma – Pipeline by Sanofi, H1 2017

High-Grade Glioma – Pipeline by Sorrento Therapeutics Inc, H1 2017

High-Grade Glioma – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

High-Grade Glioma – Pipeline by Targepeutics Inc, H1 2017

High-Grade Glioma – Pipeline by Tocagen Inc, H1 2017

High-Grade Glioma – Pipeline by ZIOPHARM Oncology Inc, H1 2017

High-Grade Glioma – Dormant Projects, H1 2017

High-Grade Glioma – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for High-Grade Glioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports